Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
2017-08-21
Target enrollment:
Participant gender:
Summary
The objective of this pilot study is to evaluate the efficacy of intensive fixed monthly
dosing of intravitreal Lucentis® (Ranibizumab) for the treatment of SRF and PED in
neovascular AMD which is persistent to anti-VEGF (anti-vascular endothelial growth factor)
monotherapy.